The drugmaker plans to acquire 33 percent stake in Avenue Therapeutics for $35 million at $6 per share, according to its stock exchange notification.
Shares of the pharmaceutical company fluctuated between gains and losses to trade at Rs 528.40.
The drugmaker plans to acquire 33 percent stake in Avenue Therapeutics for $35 million at $6 per share, according to its stock exchange notification.
Shares of the pharmaceutical company fluctuated between gains and losses to trade at Rs 528.40.
Equity benchmarks in Japan and South Korea were little changed as trading began, while Australian stocks declined. Futures indicated Hong Kong shares would nudge higher after sliding into a bear market. The Singapore-traded SGX Nifty, an early indicator of NSE Nifty 50 Index’s performance in India, traded 0.3 percent higher at 11,349.50 as of 7:20 a.m.
Technical Power of CFA’s
(CHARTRED FINANCE ANALYST)
Stocks Check: Cipla, State Bank Of India And More 📌 State Bank of India won’t be able to merge more banks with self. 📌 UPL-led consortium is in exclusive talks to acquire Bill Ackman-backed Platform Specialty Products Corp. 📌 Cipla gets final approval for generic drug Sustiva. 📌 The wealth management …
Gold Silver Reports (GSR) – Stocks To Watch: Axis Bank, Bharti Infratel, Cipla, Reliance, LIC Housing – The Singapore-traded SGX Nifty, an early indicator of NSE Nifty 50 Index’s performance in India, fell 0.5 percent to 10,554 as of 7:20 a.m. Asian stocks had a mixed start Monday, with investors continuing to assess the outlook for trade discussions and geopolitical tensions. Equity benchmarks rose in Sydney, while those in Tokyo and Seoul were little changed.
Gold Silver Reports (GSR) – Stocks To Watch: Bandhan Bank, Cipla, IDFC Bank, Mindtree, NMDC — Stocks in Asia followed their U.S. counterparts higher on signs that an escalation of trade tensions was beginning to ease.
The Singapore-traded SGX Nifty, an early indicator of NSE Nifty 50 Index’s performance in India, rose 0.2 percent at 10,174.50 as of 7:20 a.m.
Gold Silver Reports – Cipla Says Eight Observations By U.S. FDA For Goa Unit Are Procedural — Cipla Ltd. received eight observations regarding manufacturing practices at its Goa plant that contributes a quarter of the drugmaker’s sales in the U.S.